Experts Evaluate Role of MRD Testing in Guiding Multiple Myeloma Treatment Duration
Hematology specialists discussed how minimal residual disease testing might help tailor the length of multiple myeloma therapy while balancing patient risk and quality of life.
❤️Conditions & CarePhoto: medpagetoday.com
Key points
- City of Hope hematologists discussed using minimal residual disease testing to evaluate the duration of multiple myeloma maintenance therapy.
- Sustained negative testing over two to three years may provide confidence to adjust therapy in standard-risk patients.
- An estimated 5% to 7% of patients never achieve negative residual disease status but still maintain good long-term outcomes.
Hematology experts from City of Hope recently evaluated the evolving role of minimal residual disease testing in determining treatment duration for individuals with multiple myeloma. In a expert panel led by Dr. Joseph Mikhael, along with Dr. Amrita Krishnan and Dr. Tulio Rodriguez, clinicians discussed whether achieving minimal residual disease negativity—a standard indicating that highly sensitive tests detect no remaining cancer cells—can help determine when maintenance therapy might be safely adjusted or stopped.
While undetectable residual disease correlates with longer progression-free and overall survival, panel members stressed that treatment decisions cannot rely on testing results alone. Genomic risk profiles and clinical features such as extramedullary disease remain critical factors. For standard-risk patients, experts often look for sustained negative test results over two to three years before considering changes to therapy. Ongoing research, including the DRAMMATIC study, is assessing whether patients with negative testing at two years can discontinue maintenance, building on prior data from trials like FORTE that monitored sustained response over longer periods.
The specialists highlighted several practical limitations, noting that clear clinical guidelines are still lacking for patients who remain persistently positive on testing. Furthermore, roughly 5% to 7% of individuals with lower-risk disease never achieve undetectable residual status yet experience favorable long-term survival. Managing ongoing side effects such as fatigue and continuous gastrointestinal symptoms remains an important consideration in therapy decisions. What to know: Patients should consult their healthcare team before making any changes to their cancer treatment regimen.
Source medpagetoday.com — medpagetoday.com/meetingcoverage/ashroundtablemm/123900 ↗
Read next
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…
🏃FitnessExpert Advice on Hydration Gear Sparks Debate Among Recreational Runners
Olympic medalist Josh Kerr recently suggested that runners may not require hydration packs for distances under 12 miles, igniting a broader conversation about gear necess…
🏃FitnessA Structured Approach to Beginning a Strength and Cardio Routine
A new four-week training program offers beginners a guided path to incorporating strength training and cardiovascular exercise into their daily lives.